Literature DB >> 3857234

Oral isotretinoin therapy for familial Muir-Torre syndrome.

R L Spielvogel, R L DeVillez, L C Roberts.   

Abstract

Two representative cases of familial Muir-Torre syndrome are presented. Multiple benign sebaceous neoplasms in both cases and a solitary keratoacanthoma in one were successfully treated with oral isotretinoin. Low-dose maintenance therapy has stabilized the cutaneous manifestations in the two patients, and no new epithelial neoplasms have appeared. This report emphasizes (1) the rationale for the use of isotretinoin in the Muir-Torre syndrome and (2) the potential for a familial pattern of inheritance and a possible association with the cancer family syndrome. It speculates on the prevention of future internal malignancies in Muir-Torre syndrome patients by maintenance oral isotretinoin treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3857234     DOI: 10.1016/s0190-9622(85)70066-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

Review 3.  The retinoids. A review of their clinical pharmacology and therapeutic use.

Authors:  C E Orfanos; R Ehlert; H Gollnick
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

4.  [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].

Authors:  B Gilly; A Unholzer; G Strobl-Wildemann; C Haas; H Starz; J Welzel
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

Review 5.  The skin: a mirror to the gut.

Authors:  Vishal Ghevariya; Shashideep Singhal; Sury Anand
Journal:  Int J Colorectal Dis       Date:  2013-01-18       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.